NeoGenomics, Inc.

NASDAQ:NEO

Medical - Diagnostics & Research

Healthcare
$15.29 +6.03%

+$0.63 today

Market cap
$1.99B
Beta
1.81
P/E (TTM)
-2.9
EPS (TTM)
-$3.84
52W Low $4.72High $13.74

Volume 1.09M

Average 1.94M

NEO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

NeoGenomics, Inc.NASDAQ: NEO

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income turns positive

Q2 FY2026 net income was $2.24M, compared with -$45.09M a year earlier. Trailing-twelve-month net income was -$51.88M. Over 3 fiscal years it compounded at -9.2% a year.

Context

  • Net income amounted to 14.9% of revenue in FY2025, up 2.9 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 8 analysts of $26.13M (+124.2%) for the fiscal year ending Dec 2026, a step up from the +37.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.24M+113.1% QoQ
Last fiscal yearDec 2025
-$108.03M+37.2% YoY
LTMJun 2026
-$51.88M-50.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+105.0%+126.3%+21.3 pp
1 year+37.2%+124.2%+87.0 pp
3-year CAGR-9.2%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(108.03M) USD
Year-over-year change
-37.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NEO compares with its peers on the latest reported figures

  • NEO's LTM Jun 2026 net income of $51.88M is the 7th largest of the 10 companies compared; the peer median is $95.55M.
  • Its year-over-year change of -50.1% is the 9th highest of 10, against a peer median of +21.6%.
  • Net income amounts to 6.8% of revenue for NEO, versus a peer median of 33.3%.
NEO Competitors Peer median
Net Income for NEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$485.07M +21.6%-14.0%37.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$399.9M +294.4%+48.4%48.2%
GRALGRAIL, Inc.LTM Jun 2026$391.59M -11.6%-57.7%236.9%
VCYTVeracyte, Inc.LTM Jun 2026$114.48M +334.7%—20.4%
WGSGeneDx Holdings Corp.LTM Jun 2026$106.36M -7664.5%-66.3%23.4%
PSNLPersonalis, Inc.LTM Mar 2026$95.55M +13.7%-10.5%148.1%
NEONeoGenomics, Inc.LTM Jun 2026$51.88M -50.1%-9.2%6.8%
BDSXBiodesix, Inc.LTM Mar 2026$31.96M -20.9%-18.6%33.3%
XGNExagen Inc.LTM Mar 2026$20.17M +30.0%-25.1%29.5%
CSTLCastle Biosciences, Inc.LTM Mar 2026$12.83M +153.1%-28.9%3.8%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding NEO) $95.55M+21.6%-21.8%33.3%

Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.35M)(144.25M)(87.97M)(78.73M)(108.03M)
Depreciation & Amortization53.35M69.43M72.58M72.55M67.82M
Deferred Income Tax0(16.1M)000
Stock-Based Compensation22.46M24.67M24.63M33.41M41.32M
Change in Working Capital(4.6M)(31.7M)(25.49M)(32.63M)(32.1M)
Accounts Receivables(4.69M)(7.58M)(11.52M)(19.31M)(6.18M)
Inventory1.63M(1.1M)(454K)(2.7M)(1.54M)
Accounts Payables19.33M2.8M(4.55M)(4M)(4.69M)
Other Working Capital(20.87M)(25.82M)(8.98M)(6.62M)(19.68M)
Other Non-Cash Items(89.59M)31.95M14.29M12.42M36.21M
Operating Cash Flow(26.72M)(65.99M)(1.95M)7.02M5.23M
Capital Expenditures(64.14M)(30.89M)(28.75M)(41.06M)(27.01M)
Acquisitions (Net)(419.4M)000(6.45M)
Purchases of Investments(196.79M)(97.61M)(6.76M)0(500K)
Sales of Investments62.97M116.92M112.22M53.92M20.06M
Other Investing Activities(15M)12.1M001.57M
Investing Cash Flow(632.37M)517K76.71M12.86M(12.34M)
Debt Repayment334.41M(758K)(70K)0(201.25M)
Common Stock Issued423.21M12.59M4.62M4.65M962K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(32.34M)0000
Financing Cash Flow725.29M11.83M4.55M4.65M(200.29M)
Effect of Forex Changes00000
Net Change in Cash66.2M(53.65M)79.31M24.52M(207.39M)
Free Cash Flow(90.87M)(96.88M)(30.71M)(34.04M)(21.78M)

NeoGenomics, Inc.

NASDAQ:NEO

Intrinsic Alpha fair value

Locked

Current Price

$15.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.